Antisense oligonucleotides have been used to suppress the expression of a number of oncogenes and growth factors (7-9). Point mutations represent a well-defined target for antisense oligonucleotides. We (10) and others (11, 12) 
celluar disponibility ofantsense oligonucleotides can be markedly improved by adsorption to polyalkylqvanoacrylate nano- particled. Nanoparticle-adsorbed antisense oligonucleotides directed t6a point mutat (G U) in codon 12 of the Ha-ras mRNA selectively Inhibited the proliferation of cells expressing the point-mutated Ha-ras gene at a concentration 100 times lower than free oligonucleotides. In addition they markedly inhibited Ha-rns-dependent tumor growth in nude mice after subcutaneous injection. These experiments show that inhibition of ras oncogenes by antsense oligonuceotides can block tumor development even though ras oncogenic activation might be an early event in tumor progression.
ras mutations are detected in 20-30% of human tumors (1, 2) , and in certain tumor types their expression appears to be associated with a less-favorable prognosis (3, 4) . In comparison with the ras protooncogenes, which are expressed in all cells, the ras oncogenes possess single point mutations in the sequence coding for the active site of the Ras protein, most frequently at codons 12, 13, and 61. Evidence has been accumulating that mutated ras genes are directly involved in cell proliferation and tumorigenicity (1, 2, 5, 6) . It Antisense oligonucleotides have been used to suppress the expression of a number of oncogenes and growth factors (7) (8) (9) . Point mutations represent a well-defined target for antisense oligonucleotides. We (10) and others (11, 12) have shown that the expression of mutated Ha-Ras can be suppressed selectively by antisense oligonucleotides directed against the region of the Ha-ras mRNA carrying a point mutation in codon 12. These oligonucleotides efficiently inhibit the proliferation of T24 cells that exclusively express mutated Ha-Ras (10) . Different mechanisms have been proposed to explain the activity of antisense oligonucleotides. Antisense oligonucleotides directed against, or upstream of, the AUG region of a mRNA are thought to hinder interaction of the RNA with the ribosome, thus interfering with translation. Specific cleavage of RNA-oligodeoxynucleotide hybrids by RNase H has also been demonstrated (13) . For the Ha-ras oncogene, we demonstrated that short oligonucleotides targeted to the coding sequence can induce site-specific RNA cleavage by RNase H in vitro (10) . These RNase H cleavage studies allowed us to define the optimal oligonucleotide length (12 or 13 bases) necessary to preserve the discrimination of the point-mutated region in codon 12 of the Ha-ras mRNA vs. the mRNA of the protooncogene (14) .
MATERIALS AND METHODS
Oligodeoxynucleotides. Unmodified oligonucleotides were synthesized by Genset, Paris, on an automated solid-phase synthesizer (Applied Biosystems) using phosphoramidite chemistry. The oligomers were ethanol-precipitated twice, washed with 75% ethanol, and reconstituted in water. An aliquot of each sample was labeled at the 5' end using T4 polynucleotide kinase and [32P]ATP and analyzed for homogeneity on a 20%6 polyacrylamide gel.
RNase H Cleavage Assay. Uniformly labeled capped SP6 transcripts were synthesized using an EcoRI-linearized plasmid that contains the entire coding region of normal or activated Ha-ras as described (10 Lysis buffer (500 /4; 0.15 M NaCl/10 mM Tris-HCl, pH 7.5/1.5 mM MgCl2/0.65% Nonidet P40) was added to a cell pellet containing 3-4 x 106 cells. The mixture was incubated for 5 min at 4°C. After centrifugation, the supernatant was mixed with an equal volume ofurea/SDS buffer (7 M urea/10 mM Tris HCl, pH 7.5/10mM EDTA/1% SDS). Then, protein precipitation was carried out in the presence of 2 M NaCl. The tubes were centrifuged and RNA was precipitated from the supernatant with 2 vol of ethanol. Reverse transcription and PCR (2 pg of RNA) were performed using GeneAmp RNA PCR kit according to manufacturer instructions (Perkin-Elmer/Cetus). Reactions were performed on a Hybaid Thermable reactor. As an internal standard for the quantification, human A32-microglobulin cDNA was coamplified. To ensure linear amplification, the number of cycles was limited to 25 (94°C for 50 sec, 57°C for 50 sec, and 72°C for 20 sec). The primers used were as follows: ras, 5' amplimer (5'-TGAGGAGCGATGACGGAATA-3') and 3' amplimer (5'-GTATCCAGGATGTCCAACAG-3'); f32-microglobulin, 5' amplimer (5'-AAGATGAGTATGCCTGCCGT-3'), 3' amplimer (5'-ATGCTGCTTACATGTCTCGAT-3'). Reaction products were precipitated and separated on a 7% polyacrylamide gel and visualized by ethidium bromide staining.
Oligodeoxynucleotide Uptake. Approximately 5 x 105 HBL100rasl cells were plated in 2 ml ofcomplete medium for each time point. After the cells adhered to the culture dish, 5 x 106 cpm of 5'-32P-labeled or 2 x 106 cpm of internally 32P-labeled oligonucleotide and 400 pmol of carrier oligonucleotide were added alone or after adsorption to PIHCA NPs. The 12-mer was internally labeled by ligating two 6-mers using T4 DNA ligase in the presence of a 16-mer template. The 6-mer corresponding to the 3' half of the 12-mer was 32P-labeled at its 5' end before ligation. After the indicated incubation periods, cells were harvested, total radioactivity in the medium and in the washed cell pellet was measured, and the oligonucleotides were extracted from cell lysates as described (10 
RESULTS
Point Mutation Selectivity of Antisense Oligonucleoides. In the present study three 12-mer oligonucleotides were used, (i) an antisense oligonucleotide (AS-Val, 5'-CACCGACG-GCGC-3') directed against and centered at the point mutation in codon 12 of the Ha-ras mRNA, (ii) an antisense oligonucleotide (AS-Gly, 5'-CACCGCCGGCGC-3') targeted to the equivalent sequence of the normal Ha-ras mRNA, and (iii) the 5'/3' inverted sequence of AS-Val that contains the same bases as the antisense sequence but in reverse orientation (INV-Val, 5'-CGCCGGAGCCAC-3'). Using an in vitro RNase H assay, based on HeLa cell extracts, we showed that under conditions where the mutated mRNA was completely cleaved in the presence ofAS-Val (Fig. 1, lane 1) , no cleavage was detected on wild-type mRNA (Fig. 1, lane 4) . In contrast, AS-Gly did not induce any cleavage of the mutated mRNA (Fig. 1, lane 2) , whereas it induced cleavage of the normal mRNA (data not shown (15) . We made use of this approach to adsorb AS-Val and all control oligonucleotides to PIHCA NPs in the presence of CTAB. When HBLlO0rasl and HBLl0Oneo were treated with these complexed oligonucleotides, the specific inhibitory effect of AS-Val on HBL100rasl proliferation was preserved but occurred at 100-fold lower concentration (=200 nM) than with free oligonucleotide (Fig. 2A, bars 1 condition to achieve the biological effect of the oligonucleotide at 200 nM.
Expression of Ha-ras mRNA in Cells Exposed to Anthes Dodecamer. The specific inhibition of HBLlOOrasl cell proliferation was expected to result from greatly decreased Ha-ras mRNA levels, should RNase H-induced cleavage of the mRNA be involved in the antisense effect. This was established by reverse-transcribing total RNA from cells (HBL100rasl or HBLlOOneo) untreated or treated with oligonucleotides adsorbed to NPs. Two pairs of primers were used to selectively amplify Ha-ras and P2-microglobulin mRNAs, the latter being used as a control. Fig. 2B shows that Ha-ras mRNA was specifically inhibited in HBLlOOrasl cells treated with AS-Val oligomer, whereas AS-Gly treatment did not affect Ha-ras mRNA levels when compared to untreated cells. On the contrary Ha-ras mRNA level was the same in untreated or AS-Val-exposed HBLlOOneo cells (Fig. 2B) . Wild-type mRNA disappeared in HBLl00neo cells after treatment with AS-Gly oligomer (data not shown). These studies provide evidence that the point mutation specificity of AS-Val observed in vitro was maintained within cells and that AS-Val induced a sequence-selective depletion of mutant Ha-ras mRNA in HBLlOOrasl cells.
Cellular Uptake and Stability of Free and NP-Adsorbed Dodecamers. Cellular uptake of free oligonucleotides and of oligonucleotides adsorbed to NPs is likely to follow different mechanisms. There is evidence for the existence of cell surface.proteins that bind oligonucleotides (21, 22) . Cellular incorporation of NPs was found to be much higher in cells Proc. Natl. Acad. Sci. USA 91 (1994) m P that exhibited phagocytic activity (15) . Our studies were performed with epithelial cells that do not possess a high phagocytic activity. To quantitate the amount of oligonucleotide incorporated by HBL100 cells, we treated both cell types with 32P-labeled free or NP-adsorbed oligonucleotides. Free oligonucleotide was incorporated at a slightly (-20%o) more efficient rate by HBL100neo than by HBL100rasl cells, whereas both cell lines incorporated NP-adsorbed oligonucleotide with the same efficacy (data not shown). Analysis of the intracellular oligonucleotide by gel electrophoresis revealed that the NP-adsorbed oligonucleotide was intact after 24 h and that it was still detectable 72 h after incubation, whereas the free oligonucleotide was already dephosphorylated (when 5' labeled) and degraded after 3 h (Fig. 3 and data not shown). Quantitation of intact 12-mer oligonucleotide was achieved by measurement of the radioactivity in each band cut out of the polyacrylamide gel. At all time points examined, a comparison of the amount of intact intracellular oligonucleotide revealed about 100-fold higher concentration in cells treated with NP-adsorbed oligonucleotide (Fig. 3A) . Similar results were obtained with 5'-32P-labeled 12-mer oligonucleotides and with internally 32P-labeled 12-mers showing that NPs protected oligonucleotides not only from dephosphorylation but also from degradation (Fig. 3B) experiments, a control group of mice (n = 18) were injected with PBS, whereas the AS-Val-treated group (n = 10) received a total of 52 jg of oligonucleotide given in four injections. One subcutaneous injection every 4 days at the site of the tumor led to a significant difference in growth between the antisense (average tumor weight, 24 mg) and control groups (average tumor weight, 75 mg) when excised at 14 days. In a second set of experiments, mice were treated with NP-adsorbed AS-Val or INV-Val. Local subcutaneous injection of NP-adsorbed AS-Val at the site where HBL100rasl cells had been inoculated resulted in a considerable inhibition of tumor development with an average tumor weight of 12 mg after 3 weeks (n = 9; Table 1 ). Mice treated with NP-adsorbed INV-Val oligonucleotide, on the other hand, developed large subcutaneous tumors (average tumor weight, 245 mg; n = 10), demonstrating the sequencedependent effect of the AS-Val oligonucleotide on HBL100rasl tumorigenicity (Table 1) . Analysis of this data using the Mann-Whitney test showed statistical significance with P < 0.05. During this treatment (24 days), mice received 92 pg of each oligonucleotide. In the two experiments described above, oligonucleotide treatment was started before the onset of tumors. We also carried out an experiment where the tumors were first grown for 3 days and then injection of the NP-adsorbed oligonucleotides was started. Treatment was stopped 10 days after the first injection and animals were sacrificed 21 days after the last injection. Mice received 100 pg of NP-adsorbed oligonucleotides given in five injections. Proc. Natl. Acad. Sci. USA 91 (1994) There was a 5-fold difference in growth between the antisense and control groups.
DISCUSSION
It has been shown previously that antisense oligonucleotides can inhibit the expression of oncogenes or growth factor receptors in vivo (23) (24) (25) (26) (27) (28) . However, maintaining sufficient local concentrations of intact biologically active oligonucleotide has raised a number of problems. Most experiments have used phosphorothioate oligonucleotides or 3'-phosphorothioate-substituted oligonucleotides to protect the oligomer from nuclease degradation. Regardless of the technique used to deliver the oligonucleotide [miniosmotic pumps (23, 25, 28) or local or intraperitoneal injections (24, 26, 28) (16, 29, 30) . In contrast, electron microscopy studies have confirmed the presence of undegraded NPs at the injection site 24 h after subcutaneous administration (30) . The low doses required to achieve the described biological effect could be attributed to the fact that NPs are able to improve the bioavailability ofthe dodecamers by protecting the oligonucleotides from nuclease degradation and by a slow release process within cells.
Although studies on human tumors growing in immunocompromised animals are not ideal to predict anticancer activity, our findings demonstrate the possibility of using antisense oligonucleotides to prevent tumor growth with an efficient delivery system. In addition our results show that ras oncogene inhibition in established tumorigenic cell lines may lead to a reversal of the tumorigenic phenotype. Shirasawa et al. (31) used homologous recombination to knock out mutated Ki-ras expression in human colon tumor cell lines and showed that tumorigenicity was lost in nude mice even though Ki-ras gene mutation was only one of the several genetic modifications that led to tumorigenic transformation. Thus these results show that the antisense strategy offers a promising route to inhibit the growth of ras-dependent tumors even under conditions where oncogenic ras mutation is an early event in tumor progression. Antisense oligonucleotides can be designed to block a mutated mRNA without any marked effect on the expression of the normal gene. Therefore, they should exert their antisense activity on tumor cells that express the mutant gene and have no or reduced effects on normal cells.
